We are now half-way through 2014, and much has happened during these first 6 months.

Hi-lites include:

- The most important action that we took recently is the establishment of a European affiliate (IABS-EU) with headquarters in Lyon, France. This is a landmark event in the history of IABS, and represents a significant amount of work on the part of Joris Vandeputte, Abbie Charlet, and Daniel Gaudry to whom we are very grateful. IABS-EU is now officially recognized by French authorities as a nonprofit organization (link to IABS-EU). As such, it can participate with EU partners in scientific activities. You will be hearing more about this in the months ahead.

- We held a successful conference on cell therapy in Kyoto, Japan; and we are currently working with WHO on followup steps (link to agenda for March conference). We have made significant progress in organizing two additional conferences:
  - Statistical and Data Management Approaches for Biotechnology Drug Development (link to conference)

- We participated in the 2014 WHO World Health Assembly where IABS provided comments on resolutions dealing with strengthening national regulatory agencies in developing countries, and ensuring the quality of biosimilar products (link to IABS statements).

- Preparations are underway for the next Board of Directors meeting as well as for the General Assembly in September, both of which will be held in Strasbourg in conjunction with the conference on human challenge studies.

As you can see, IABS has been very active in a variety of areas, and we look forward to continuing to make progress in the months ahead.

With best regards,

John Petricciani, MD